CLINICAL TRIALS PROFILE FOR EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

All Clinical Trials for emtricitabine; tenofovir alafenamide fumarate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01497899 ↗	Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults	Completed	Gilead Sciences	Phase 2	2011-12-28	The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF) FDC in HIV-1 infected, antiretroviral treatment-naive adults.
NCT01565850 ↗	D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults	Completed	Gilead Sciences	Phase 2	2012-04-01	This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naive adults as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24.
NCT01780506 ↗	Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults	Completed	Gilead Sciences	Phase 3	2012-12-26	The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults.
NCT01797445 ↗	Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults	Completed	Gilead Sciences	Phase 3	2013-03-12	The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) in HIV-1 positive, antiretroviral treatment-naive adults.
NCT02121795 ↗	Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF	Completed	Gilead Sciences	Phase 3	2014-05-06	This study will evaluate the efficacy of switching from emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) fixed dose combination (FDC) to emtricitabine/tenofovir alafenamide (F/TAF) FDC in HIV-1 positive participants who are virologically suppressed on regimens containing FTC/TDF. This study will consist of a 96 week double-blind treatment period. After Week 96, all participants will continue on blinded study drug treatment and attend visits every 12 weeks until treatment assignments are unblinded. All participants will return for an unblinding visit and will be given the option to receive open-label F/TAF and attend visits every 12 weeks until F/TAF is commercially available, or the sponsor terminates the F/TAF clinical development program.
NCT02251236 ↗	Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals	Completed	Gilead Sciences	N/A	2016-01-01	The project will have two tracks, one for participants who are currently taking elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or E/C/F/tenofovir alafenamide (E/C/F/TDF or E/C/F/TAF) single-tablet regimen* (STR) (Track A) and one for participants who will begin therapy with E/C/F/TDF or E/C/F/TAF STR during the study (Track B). Participants will take E/C/F/TDF and/or E/C/F/tenofovir alafenamide fumarate (E/C/F/TAF) STR** (if available) for 24 weeks. *Co-formulation of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 300 mg of tenofovir disoproxil fumarate. **Co-formulation of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamide fumarate.

Clinical Trial Conditions for emtricitabine; tenofovir alafenamide fumarate

Condition Name

Condition Name for emtricitabine; tenofovir alafenamide fumarate
Intervention	Trials
HIV-1 Infection	9
HIV	9
HIV Infections	7
HIV-1-infection	5

Condition MeSH

Condition MeSH for emtricitabine; tenofovir alafenamide fumarate
Intervention	Trials
HIV Infections	17
Acquired Immunodeficiency Syndrome	10
Immunologic Deficiency Syndromes	5
Infections	3

Clinical Trial Locations for emtricitabine; tenofovir alafenamide fumarate

Trials by Country

Trials by Country for emtricitabine; tenofovir alafenamide fumarate
Location	Trials
United States	293
Canada	39
United Kingdom	17
France	17
Spain	14

Trials by US State

Trials by US State for emtricitabine; tenofovir alafenamide fumarate
Location	Trials
California	18
Florida	17
Georgia	15
Texas	15
District of Columbia	14

Clinical Trial Progress for emtricitabine; tenofovir alafenamide fumarate

Clinical Trial Phase

Clinical Trial Phase for emtricitabine; tenofovir alafenamide fumarate
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	1
PHASE1	1

Clinical Trial Status

Clinical Trial Status for emtricitabine; tenofovir alafenamide fumarate
Clinical Trial Phase	Trials
Completed	22
Recruiting	8
Not yet recruiting	7

Clinical Trial Sponsors for emtricitabine; tenofovir alafenamide fumarate

Sponsor Name

Sponsor Name for emtricitabine; tenofovir alafenamide fumarate
Sponsor	Trials
Gilead Sciences	25
National Institute of Allergy and Infectious Diseases (NIAID)	3
Radboud University Medical Center	2

Sponsor Type

Sponsor Type for emtricitabine; tenofovir alafenamide fumarate
Sponsor	Trials
Other	47
Industry	31
OTHER_GOV	3

Emtricitabine / Tenofovir Alafenamide Fumarate: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 28, 2026

What is the current clinical-state of emtricitabine (FTC) + tenofovir alafenamide fumarate (TAF) fixed-dose combinations?

FTC + TAF is used in multiple approved fixed-dose regimens, with the most commercially standardized combination being Descovy (FTC/TAF) for HIV treatment and prevention indications (labeling varies by jurisdiction). Clinical activity for FTC/TAF in 2024-2026 is dominated by:

• Post-approval lifecycle studies (safety follow-up, co-morbidity subsets, switching or continuation strategies).
• Comparative and adherence-focused studies evaluating regimen simplification or fixed-dose maintenance.
• Real-world program data (often published in journals with protocol origins tied to registration datasets).
• Formulation and population expansion studies (pediatric and renal/bone-safety subgroups), typically tied to label broadenings rather than novel mechanisms.

Regimen context (mechanism stays constant):

• FTC: nucleoside reverse transcriptase inhibitor (NRTI).
• TAF: tenofovir prodrug with lower systemic tenofovir exposure vs TDF, with clinical emphasis on renal and bone safety.

What to track for pipeline relevance (practical checklist):

• Studies that target switching from TDF-based regimens to TAF-based regimens, or treatment simplification while maintaining virologic suppression.
• Studies that evaluate renal function decline, bone mineral density markers, and tenofovir exposure proxies.
• Trials focused on persistence and adherence, because FTC/TAF market share depends on retention economics (formulary position, pharmacy channels, and payer authorization).

Which clinical readouts drive uptake and payer confidence for FTC/TAF?

Across the FTC/TAF category, payer confidence tends to be anchored to three measurable endpoints that show up repeatedly in updates:

1. HIV-1 viral suppression (standard proportion of patients achieving and maintaining HIV RNA below assay thresholds).
2. Renal safety (eGFR trends, proteinuria markers, creatinine clearance changes).
3. Bone outcomes (bone mineral density, bone turnover markers, fracture incidence).

TAF is positioned on reduced renal and bone burden compared with TDF-containing regimens, which directly affects:

• Prior authorization defensibility.
• Long-term formulary placement in patients with baseline CKD risk.
• Clinician willingness to keep patients on the same backbone regimen.

These endpoints are also the ones most commonly revisited in lifecycle publications and subgroup analyses after initial pivotal programs.

---

What is the market structure for emtricitabine/tenofovir alafenamide?

FTC/TAF market dynamics are shaped by three factors: (1) high baseline adoption for HIV therapy, (2) prevention use in appropriate-risk populations where indicated, and (3) competitive intensity from other NRTI backbones and integrase-centered single-tablet regimens.

Market segments

• Treatment (ART): fixed-dose backbones embedded in combination regimens.
• Prevention (PrEP): FTC/TAF is used where label permits, with country-specific restrictions based on study evidence and regulator determinations.
• Switch and retention: patients moving from older TDF-based regimens to TAF to reduce renal/bone toxicity risk.

Pricing and access mechanics

FTC/TAF economics are driven less by unit cost alone and more by:

• Formulary tiering and pharmacy benefit design.
• Prior authorization criteria tied to renal parameters and documented intolerance to alternatives.
• Copay programs and patient assistance where permitted.
• Competition from generic tenofovir backbones in markets where exclusivity has ended (varies by geography and salt/formulation).

---

How does competition shape the projection for FTC/TAF?

FTC/TAF competes primarily as an NRTI backbone within broader HIV regimen ecosystems dominated by integrase inhibitors. The competitive set splits into:

• TDF-based NRTI backbones: lower acquisition cost, but higher renal/bone signal.
• Alternative nucleosides combined with other tenofovir formulations or other prodrugs.
• Single-tablet combinations that displace multi-pill regimens.

TAF’s wedge is safety and long-horizon tolerability, which supports:

• Continuation vs switching away for renal or bone issues.
• Clinician preference for patients with risk factors.

As generic TDF-based regimens compress cost, FTC/TAF volume growth depends on whether payers continue to approve TAF-based regimens for appropriate patient cohorts and whether competitors do not undercut with similarly strong safety evidence.

---

What are the market projections for FTC/TAF (growth drivers, base case, and downside)?

The following projection framework ties directly to how HIV formularies evolve.

Base-case demand drivers

• Continued ART and PrEP programs with regimen retention.
• Ongoing switching from TDF toward TAF in CKD and older-patient cohorts.
• Expansion of patient eligibility as safety data accumulates in real-world datasets.

Key dampeners

• Generic displacement and contract pricing pressure in treatment lines.
• Formulary restrictions for PrEP and/or treatment initiation in some geographies.
• Therapy guideline updates that steer first-line combinations toward other backbones.

Projection model (directional, revenue- and volume-linked)

Given FTC/TAF’s maturity and label footprint, the near-term market trajectory is typically:

• Low-to-mid single-digit growth in developed markets where payer controls are tight.
• Moderate growth where access programs expand and where TAF has substitution advantages for renal/bone risk patients.
• Volatility by jurisdiction due to generic timing and policy.

Market outcome summary (directional):

• Volume: steady growth from program expansion and switching.
• Value: constrained growth if generic and contract pricing intensify; better resilience where TAF remains preferred by safety criteria.

---

What clinical evidence and regulator signals matter for long-term adoption?

For FTC/TAF, the regulatory logic and clinician adoption logic remain consistent:

• TAF is used to mitigate renal and bone safety concerns seen with older tenofovir formulations.
• Lifecycle studies that reaffirm that benefit in broader populations protect uptake, especially among:
  • Patients with baseline mild CKD risk.
  • Older adults.
  • Long-duration ART patients where cumulative toxicity matters.

Clinically meaningful updates tend to show up in:

• Renal function endpoints over time.
• Bone density trajectories.
• Switch durability (virologic maintenance after conversion from TDF-based regimens).

---

Which major trial themes should investors prioritize for future differentiation?

FTC/TAF’s molecule-level innovation risk is low because the mechanism is established. The differentiation risk sits in the program around it:

• Regimen simplification trials (switching and maintenance strategies).
• Real-world effectiveness and safety confirmation (renal and bone).
• PrEP persistence and adherence-linked outcomes.
• Population expansions that widen eligibility under payer constraints.

If future updates show durable suppression with stable or improved renal/bone safety in broader subsets, FTC/TAF maintains pricing and share stability. If competitive backbones show comparable safety with lower cost, share pressure increases.

---

Key Takeaways

• FTC/TAF is a mature, standardized HIV regimen backbone where clinical updates focus on lifecycle confirmation: viral suppression, renal safety, and bone outcomes.
• Market growth is primarily driven by retention and switching from TDF to TAF in patients with renal or bone risk, supported by payer authorization frameworks that rely on safety evidence.
• Projections are best treated as steady volume growth with value growth constrained by generic displacement and contracting pressure, with jurisdiction-specific volatility.
• Future investor attention should center on studies that protect or expand eligibility under payer rules: renal function trajectories, bone safety durability, and PrEP persistence.

---

FAQs

1) Is FTC/TAF still expanding clinically?

Yes, updates in the FTC/TAF space skew toward post-approval studies and subgroup evidence that support label-relevant use, especially renal and bone safety in broader patient groups.

2) What endpoints most influence adoption for FTC/TAF?

HIV viral suppression plus longitudinal renal safety and bone outcomes are the recurring endpoints that map directly to formulary and prior authorization decisions.

3) How does TDF competition affect FTC/TAF pricing?

TDF-based options typically compress acquisition economics. FTC/TAF pricing resilience depends on payers continuing to approve TAF for appropriate risk cohorts where TAF’s safety profile reduces long-term clinical and administrative friction.

4) What drives PrEP uptake for FTC/TAF?

Eligibility rules, payer coverage, and persistence/adherence outcomes. Trial and real-world confirmation of adherence-linked persistence supports sustained demand.

5) Where is the highest share-risk for FTC/TAF?

Geographies or payer systems where competing backbones deliver similar safety at lower cost, plus cases where guidance shifts first-line preferences away from FTC/TAF.

---

References

[1] U.S. Food and Drug Administration. Drug Approval Reports and Labeling for Descovy (emtricitabine/tenofovir alafenamide). FDA website.